Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05610527 · ClinicalTrials.gov registry record

Hormonal Influences on Inflammatory Bowel Diseases

A clinical trial, sponsored by University of Utah.

Completed
Registry status
50
Enrollment target

NCT05610527: Completed study, sponsored by University of Utah.

NCT05610527 is a clinical trial that has completed, run by University of Utah. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05610527 has completed, sponsored by University of Utah.

COMPLETED
Registry status
50 participants
Enrollment target

Study Summary

Of the 1.8 million females with inflammatory bowel diseases (IBD) in the US, over half of those who are premenopausal suffer from cyclical menstrual-related IBD symptoms, regardless of how well their disease is controlled. Despite the significant impact that cyclical IBD symptoms, such as abdominal pain, diarrhea, and fatigue have on quality of life, evidence about how to alleviate these symptoms is lacking. In other chronic conditions which are hormonally influenced, such as epilepsy, hormonal contraception may be used to favorably impact disease-related symptoms associated with menses and improve quality of life. In our previous cross-sectional study, 47% of the levonorgestrel intrauterine device users and 19% of combination oral contraceptive users reported improvement in their cyclical IBD symptom. All hormonal methods may plausibly improve symptoms, but prospective, rigorous data evaluating their efficacy for this purpose are lacking. In order to design a future comparative effectiveness trial on the effect of hormonal contraceptive methods on menstrual-related IBD symptoms, we propose this pilot prospective cohort study of 200 females with IBD: 100 naturally cycling and 100 hormonal contraception users. We will gain essential knowledge on IBD-specific influences on contraceptive method selection, willingness to be randomized to methods, the ability of IBD patient reported outcome (PRO) instruments to differentiate between non-menstrual and menstrual-related IBD symptoms, and assess the potential role of inflammatory markers as outcome measures in future trials. We will recruit participants from the University of Utah IBD Center and clinics, other Utah gastroenterology providers, and through social media ads. Total study commitment will be \~12 weeks. Study activities will include daily and weekly text message surveys, as well as blood draws and fecal samples for inflammatory markers in a subset of participants which are commonly used for IBD management. Our ai

Primary Outcome

Proportion of participants willing to be randomized in each hypothetical study scenario based on the adapted 7-item Attitudes to Randomized Trials Questionnaire and Proportion of participants who select each hormonal methods vs non-hormonal and characteristics as desirable

Interventions

  • OTHER Proposed study design and randomization scenarios
  • OTHER Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments
  • OTHER Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-07-01
Est. Completion 2025-12-09
University of Utah

818 total trials

What the finished NCT05610527 record still lists

NCT05610527 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.

The record links to 0 conditions, and to 3 interventions - of which Proposed study design and randomization scenarios is the first listed.

NCT05610527 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05610527 about?

NCT05610527 is a clinical study titled "Hormonal Influences on Inflammatory Bowel Diseases". Of the 1.8 million females with inflammatory bowel diseases (IBD) in the US, over half of those who are premenopausal suffer from cyclical menstrual-related IBD symptoms, regardless of how well their disease is controlled. Despite the significant impact that cyclical IBD symptoms, such as abdominal ...

What is the current status of trial NCT05610527?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2025-07-01. Estimated completion is 2025-12-09.

What interventions are being tested in trial NCT05610527?

The interventions under investigation include: Proposed study design and randomization scenarios (OTHER), Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments (OTHER), Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing (OTHER).

Who is sponsoring clinical trial NCT05610527?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05610527, the US trial registry maintained by the National Library of Medicine. NCT05610527 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.